A New Era: Apotex Gets Fresh Leadership As SK Completes Acquisition

Industry Veteran Allan Oberman Takes The Reins As CEO Of Canadian Generics Giant

As SK Capital Partners completes its acquisition of Apotex, generics industry veteran Allan Oberman has been named as the new president and CEO of the Canadian giant, replacing Jeff Watson who will remain on the company’s board.

Leadership change CEO wooden blocks
Allan Oberman has replaced Jeff Watson at the top of Apotex • Source: Shutterstock

Fresh leadership has been installed at Apotex, as the Canadian generics giant announced the completion of its acquisition by funds advised by SK Capital Partners.

Off-patent industry veteran Allan Oberman has been named as the new president and CEO of Apotex, replacing Jeff Watson who...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Leadership

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C5

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C4

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

Wagner Adds Germany To Role As Stada Simplifies Structure

Steffen Wagner has taken over as Stada’s head of Germany, adding to his existing responsibilities in Europe, after Eelco Ockers stepped down from the role. Ockers’ departure comes as German generics giant Stada restructures its business to bring its branded and consumer health interests into closer alignment as part of a more streamlined model.

More from Generics Bulletin

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C9

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C8

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C7

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.